FDA Approves New Octapharma Treatment For Patients With Hemophilia A

September 15, 2015

Note: This is an edited form of a press release from Octapharma. To read the original release in its entirety, click here. Octapharma USA announced on September 15, 2015, that the U.S. Food and Drug Administration (FDA) has approved NUWIQ®, Antihemophilic Factor (Recombinant), an intravenous therapy for adults and children living with Hemophilia A. The NUWIQ® […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.